Cholinesterases and cholinesterase inhibitors

Current Enzyme Inhibition

Volumn 4, Issue 4, 2008, Pages 160-171

  Štěpánkova, Šarka ^a   Komers, Karel ^a  

^a UNIVERSITY OF PARDUBICE   (Czech Republic)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Cholinesterases

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; EPTASTIGMINE; GALANTAMINE; HUPERZINE A; HUPERZINE B; MEMANTINE; METRIFONATE; NAMEDA; NEUROTRANSMITTER; PHYSOSTIGMINE; PSYCHOTROPIC AGENT; RIVASTIGMINE; TACRINE; UNCLASSIFIED DRUG;

AGITATION; ALZHEIMER DISEASE; AMNESIA; APATHY; CLINICAL TRIAL; COGNITIVE DEFECT; COMPETITIVE INHIBITION; DAILY LIFE ACTIVITY; DEGENERATIVE DISEASE; DEPRESSION; DRUG APPROVAL; DRUG BINDING; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME STRUCTURE; HUMAN; HYDROLYSIS; IRRITABILITY; LEARNING DISORDER; MENTAL DISEASE; MUSCLE WEAKNESS; NEUROLOGIC DISEASE; NONHUMAN; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; REVIEW; SEDATION; SYMPTOM; SYNTHESIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 65749099856     PISSN: 15734080     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340808786733631     Document Type: Review

References (65)

1. Oliveira, A.A.; Hodges, H3.M. Alzheimer's Disease and Neuronal Transplantation as Prospective Cell Therapy. Curr. Alzheimer Res., 2005, 2, 79-95.
2. Davis, K.L.; Charney, D.; Coyle, J.T.; Nemeroff, Ch. Neuropsychopharmacology: The Fifth Generation of Progress, 5th ed., Lippincott, Williams & Wilkins: Philadelphia, 2002.
3. Lahiri, D.K.; Farlow, M.R.; Greig, N.H.; Sambamurti, K. Current Drug Targets for Alzheimer's Disease Treatment. Drug Dev. Res., 2002, 56, 267-281.
4. Cummings, B.J.; Pike, C.J.; Shankle, R.; Cotman, C.W. β-Amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol. Aging, 1996, 17, 921-933.
5. Davis, J.N.; Chisholm, J.C. The 'amyloid cascade hypothesis' of AD: decoy or real McCoy?. Trends Neurosci., 1997, 20, 558-559.
6. Sramek, J.J.; Zarotsky, V.; Cutler, N.R. Review of drug Development and Therapeutic Role of Cholinesterase Inhibitors in Alzheimer's Disease. Drug Dev. Res., 2002, 56, 347-353.
7. Giacobini, E. In: Cholinesterases and cholinesterase inhibitors; Ezio Giacobini, Ed.; Martin Dunitz Ltd.: London, 2000, pp. 181-226.
8. Benzi, G.; Moretti, A. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of AD? Eur. J. Pharmacol., 1998, 346, 1-13.
9. www.ahaf.org (American Health Assistance Foundation, Alzheimer's Disease Research program).
10. Wilkinson, D. Pharmacotherapy of Alzheimer's disease. Psychiatry, 2007, 7, 9-14.
11. Grutzendler, J.; Morris, J.C. Cholinesterase Inhibitors for Alzheimer's Disease. Drugs, 2001, 61, 41-52.
12. Augustinsson, K.-B. Comparative Aspects of the Purification and Properties of Cholinesterases. B World Health Organ., 1971, 44, 81-89.
13. Massoulié, J.; Pezzementi, L.; Bon, S.; Krejci, E.; Vallette, F.-M. Molecular and cellular biology of cholinesterases. Prog. Neurobiol., 1993, 41, 31-91.
14. Tougu, V. Acetylcholinesterase: Mechanism of Catalysis and Inhibition. Curr. Med. Chem. - Central Nervous System Agents, 2001, 1, 155-170.
15. Barak, D.; Ordentlich, A.; Kaplan, D.; Kronman, C.H.; Velan, B.; Shafferman, A. Lessons from functional analysis of AChE covalent and noncovalent inhibitors for design of AD therapeutic agents. Chem. Biol. Interact., 2005, 157-158, 219-226.
16. Çokuǧraş, A. N. Butyrylcholinesterase: Structure and Physiological Importance. Turk. J. Biochem., 2003, 28, 54-61.
17. Giacobini, E. A Valid Alternative for Therapy of Alzheimer's Disease? Drug Aging, 2001, 18, 891-898.
18. Masson, P.; Xie, W.; Froment, M.T.; Lockridge, O. Effects of mutations of active site residues and amino acids interacting with Ω loop on substrate activation of butyrylcholinesterase. Biochim. Biophys. Acta, 2001, 1544, 166-176.
19. Dave, K.R.; Syal, A.R.; Katyare, S.S. Tissue cholinesterases. A comparative study of their kinetic properties. Z. Naturforsch, 2000, 55c, 100-108.
20. Nolte, H.J.; Rosenberry, T.L.; Neumann, E. Effective charge on acetylcholinesterase active sites determined from the ionic strenght dependence of association rate constants with cationic ligands. Biochemistry, 1980, 19, 3705-3711.
21. Sussman, J.L.; Harel, M.; Frolow, F.; Oefner, C.; Goldman, A.; Toker, L.; Silman I. Atomic structure of acetylcholinesterase from Torpedo Californica: A prototypic binding protein. Science, 1991, 253, 872-879.
22. Vellom, D.C.; Radić, Z.; Li, Y.; Pickering, N.A.; Camp, S.; Taylor, P. Amino acid residues controlling acetylcholinesterase and butyrylcholinesterase specifity. Biochemistry, 1993, 32, 12-17.
23. Lin, G.; Lai, Ch-Y.; Liao, W-Ch. Molecular Recognition by Acetylcholinesterase at the Peripheral Anioni Site: Structure-Activity Relationships for Inhibitions by Aryl Carbamates. Bioorgan. Med. Chem., 1999, 7, 2683-2689.
24. Jann, M.W.; Shirley, K.L.; Small, G.W. Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors. Clin. Pharmacokinet., 2002, 41, 719-739.
25. Brufani, M.; Filocamo, L. In: Cholinesterases and Cholinesterase inhibitors; Ezio Giacobini, Ed.; Martin Dunitz Ltd.: London, 2000, pp. 27-46.
26. Hofer, P.; Fringeli, U.P. Acetylcholinesterase Kinetics. Biophys. Struct. Mech., 1981, 8, 45-59.
27. Zdražilová, P.; Štětpácanková, Š.; Vránová, M.; Komers, K.; Komersová, A.; Čegan, A. Kinetics of Total Hydrolysis of Acetylcholine and Acetylthiocholine. Z. Naturforsch, 2006, 61c, 289-294.
28. Camps, P.; Muños-Torrero, D. Cholinergic Drugs in Pharamcotherapy of Alzheimer's Disease. Mini-Rev. Med. Chem., 2002, 2, 11-25.
29. Zhao, B.; Moochhala, S.M.; Tham, S.-Y. Biologically active components of Physostigma venenosum. J. Chromatogr. B, 2004, 812, 183-192.
30. Bachurin, S. O. Medicinal Chemistry Approaches for the Treatment and Prevention of Alzheimer's Disease. Med. Res. Rev., 2003, 23, 48-88.
31. Thal, L.; Fuld, P.A.; Masur, D.M.; Sharpless, N.S. Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann. Neurol., 1983, 13, 491-496.
32. Davis, K.L.; Mohs, R.S. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am. J. Psychiatry., 1982, 139, 1421-1424.
33. Giacobini, E. Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochem. Int., 1998, 32, 413-419.
34. Gauthier, S. Cholinergic Adverse Effects of Cholinesterase Inhibitors in Alzheimer's Disease. Drug Aging, 2001, 18, 853-862.
35. Ormrod, D.; Spencer, C. Metrifonate: A review of its use in Alzheimer's disease. CNS Drugs, 2000, 13, 443-467.
36. Kuča, K.; Bielavský, J.; Cabal, J.; Kassa, J. Synthesis of a New Reactivator of Tabun-Inhibited Acetylcholinesterase. Bioorg. Med. Chem. Lett., 2003, 13, 3545-3547.
37. Worek, F.; Koller, M.; Thiermann, H.; Szincz, L. Diagnostic aspects of organophosphate poisoning. Toxicology, 2005, 214, 182-189.
38. Amenta, F.; Parnetti, L.; Gallai, V.; Wallin A. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? Mech. Ageing Dev., 2001, 122, 2025-2040.
39. Kerkut, G.A. Acetylcholinestrase (ACHE) (EC 3.1.1.7). Gen. Pharmacol., 1984, 15, 375-378.
40. Watkins, P.B.; Zimmerman, H.J.; Knapp, M.J.; Gracon, S.I.; Lewis, K.W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA, 1994, 271, 992-998.
41. Cummings, J.L. A New Class of Psychotropic Compounds. Am. J. Psychiatry., 2000, 157, 4-15.
42. Nielsen, J. A.; Mena, E.E.; Williams, I.H.; Nocerini, M.R.; Liston, D. Correlation of brain levels of 9-amino-1,2,3,4-tetra-aminoacridine (THA) with neurochemical and behavioural changes. Eur. J. Pharmacol., 1989, 173, 53-64.
43. Freeman, S.E.; Dawson, R.M. Tacrine: A pharmacological review. Prog. Neurobiol., 1991, 36, 257-277.
44. Nightingale, S.L. Donepezil approved for treatment of Alzheimer's disease. JAMA, 1997, 277, 10.
45. Rogers, S.L.; Friedhoff, L.T. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br. J. Clin. Pharmacol., 1998, 46 (Suppl. 1), 1-6.
46. Sugimuto, H.; Iimura, Y.; Yamanishi, Y.; Yamatsu K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J. Med. Chem., 1995, 38, 4821-4829.
47. Švestka, J. Cognitive enhancer donepezil. Psychiatry, 1999, 1, 36-42. In Czech.
48. Weinstock, M.; Razin, M.; Chorev, M.; Tashma Z. In: Advances in Behavioral Biology; Fisher, A.; Hanin, I.; Lachman, P., Ed.; Plenum Press: New York, 1986, 539-551.
49. Enz, A.; Amstutz, R.; Boddeke, H.; Gmelin, G.; Malanowski, J. Brain selective inhibition of acetylcholinesterase. A novel approach to therapy for Alzheimer's disease. Prog. Brain Res., 1993, 98, 431-438.
50. Rosler, M.; Anand, R.; Cicin-Sain, A.; Gauthier, S.; Agid, Y.; Dal-Bianco, P.; Stähelin, H.B.; Hartman, R.; Gharabawi, M. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trail. Br. Med. J., 1999, 318, 633-638.
51. Zurad, E.G. New Treatments for Alzheimer's Disease. Drug Benefit Trends, 2001, 13, 27-40.
52. Maelicke, A.; Albuquerque, X. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur. J. Pharmacol., 2000, 393, 165-170.
53. Coyle, J.; Kershaw, P. Galanthamine, a Cholinesterase Inhibitor that Allosterically Modulates Nicotinic Receptors: Effects on the Course of Alzheimer's disease. Biol. Psychiatry., 2001, 49, 289-299.
54. Thomsen, T.; Zendeh, B.; Fischer, J.P.; Kewitz, H. In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers. Biochem. Pharmacol., 1991, 41, 139-141.
55. Greenblatt, H.M.; Dvir, H.; Silman, I.; Sussman, J.L. Acetylcholinesterase. J. Mol. Neurosci., 2003, 20, 369-383.
56. Thal, L.J.; Schwartz, G.; Sano, M.; Weiner, M.; Knopman, D.; Harrell, L.; Bodenheimer, S.; Rossor, M.; Philpot, M.; Schor, J.; Goldberg, A. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology, 1996, 47, 1389-1395.
57. Sramek, J.J.; Block, G.A.; Reines, S.A.; Sawin, S.F.; Barchowsky, A.; Cutler, N.R. A multi-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase. Life Sci., 1995, 56, 319-326.
58. Imbimbo, B.P.; Martelli, P.; Troetel, W. M.; Lucchelli, F.; Lucca, U.; Thal, L. J. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. Neurology, 1999, 52, 700-708.
59. Roger, S.L.; Friedhoff, T. The efficacy and safety of Donepezil in patients with Alzheimer's disease: Results of U.S. multicentre, randomized, double-blind, placebo-controlled trial. Dementia, 1996, 7, 293-300.
60. Conn, D.K. Cholinesterase inhibitors. Comparing the options for mild-to-moderate dementia. Geriatrics, 2001, 56, 56-57.
61. Zdražilová, P.; Štěpánková, Š.; Komersová, A.; Vránová, M.; Komers, K.; Čegan, A. Kinetics of 13 New Cholinesterase Inhibitors. Z. Naturforsch, 2006, 61c, 611-617.
62. Komersová, A.; Masopustová, M.; Komers, K.; Štěpánková, Š.; Čegan, A. In vitro Inhibition of cholinesterase by Carbamates - Kinetic Study. Z. Naturforsch, 2007, 62c, 305-307.
63. Štěpánková, Š.; Komers, K.; Komersová, A.; Masopustová, M.; Čegan, A. Inhibition of Cholinesterase by Dialkylcarbamates. Z. Naturforsch, 2007, 62c, 308-310.
64. 50. Z. Naturforsch, 2002, 57c, 496-499.
65. Zdražilová, P.; Štěpánková, Š.; Komers, K.; Ventura, K.; Čegan, A. Half-inhibition Concentrations of New Cholinesterase Inhibitors. Z. Naturforsch, 2004, 59c, 293-296.